Company Insights

XOMA customer relationships

Explore interactive graphBrowse insights index
XOMA customer relationship map

XOMA Customer Relationships: Royalties, Licenses and the Cash‑Flow Map

XOMA is a biotech royalty aggregator that monetizes intellectual property through licensing, milestone and royalty receipts, and the sale of future revenue streams; the company earns cash from both marketed products and development‑stage programs across the U.S., Europe and Asia‑Pacific. Investors should view XOMA as a non‑operational cash engine that converts biotech deal flow into recurring and milestone payments, with a portfolio that blends near‑term income with higher upside clinical assets. Learn more about portfolio analytics and signals at https://nullexposure.com/.

How the partner map generates dollars — a quick take

XOMA’s customer relationships are a mix of large pharmaceutical licensors and smaller biotechs that pay royalties, milestones, or provide contingent receipts tied to clinical or commercial events. The practical consequence is a revenue mix anchored in licensing and royalty cash flows rather than product sales or manufacturing economics. Below I walk through every relationship referenced in public filings and reporting, with concise source citations for each.

Pierre Fabre

XOMA’s FY2024 10‑K records that Kinnate sold exarafenib and related IP to Pierre Fabre for an upfront $0.5 million and contingent consideration of $30.5 million tied to a specified milestone, reflecting a structured milestone payment profile in the portfolio (XOMA 2024 Form 10‑K).

Novartis — gevokizumab

A 2017 FierceBiotech report states that Novartis acquired the rights to XOMA’s gevokizumab, a historical disposition of an asset that removed a development burden while converting future value into an upfront/out‑license arrangement (FierceBiotech, 2017).

Novartis — TGF‑beta programs

A Novartis media release from 2015 confirms that Novartis obtained development and commercialization rights to XOMA’s TGF‑beta antibody programs, illustrating XOMA’s use of out‑licensing to large developers (Novartis press release, 2015).

Agenus Inc.

PredictStreet coverage (Dec 2025) documents that XOMA received a $1 million milestone tied to Agenus activity related to Merck’s advancement of MK‑4830 into Phase 2, demonstrating milestone cash flows sourced from third‑party program progress (PredictStreet / FinancialContent, 2025).

Takeda — royalty‑sharing amendment

A GlobeNewswire release (Dec 30, 2025) describes a strategic royalty‑sharing transaction with Takeda that reduced Takeda’s direct obligations on mezagitamab while converting XOMA’s interest into low‑ to mid‑single‑digit royalties and milestone payments across a basket of nine development‑stage assets held in Takeda’s externalized portfolio (GlobeNewswire, Dec 2025).

Day One Biopharmaceuticals

Market reporting (PredictStreet, Dec 2025) shows XOMA received significant milestone proceeds, including a $9 million payment following FDA approval of Day One’s OJEMDA, representing direct cash realization from partner regulatory success (PredictStreet / FinancialContent, 2025).

Moderna (via Generation Bio)

A GlobeNewswire release (Dec 15, 2025) notes XOMA Royalty’s agreement to acquire Generation Bio exposure that includes a share of proceeds from Generation Bio’s license with Moderna — structured so that CVR holders could receive up to 90% of such payments, concentrating upside from large‑partner milestones (GlobeNewswire, Dec 2025).

Medexus Pharmaceuticals

PredictStreet reporting lists IXINITY, a recombinant Factor IX partnered with Medexus, as a mid‑single‑digit royalty paying product within XOMA’s portfolio, representing marketed therapy cash flow (PredictStreet / FinancialContent, 2025).

Viracta Therapeutics

PredictStreet documents an $8.1 million payment to XOMA related to a Priority Review Voucher sale from Viracta, an example of non‑traditional milestone monetization that delivers lump‑sum cash (PredictStreet / FinancialContent, 2025).

Daré Bioscience

XOMA holds an interest in Ovaprene®, a hormone‑free contraceptive partnered with Daré, indicating coverage of specialty women’s health products that contribute royalty income (PredictStreet / FinancialContent, 2025).

Zevra Therapeutics

PredictStreet identifies MIPLYFFA (arimoclomol) as a partner program with a mid‑single‑digit royalty rate, showing XOMA’s exposure to neurotherapeutic and rare disease candidates (PredictStreet / FinancialContent, 2025).

AVEO Oncology

Ficlatuzumab (AV‑299), an HGF antibody partnered with AVEO Oncology (LG Chem), is reported with a low‑single‑digit royalty rate, illustrating XOMA’s footprint in oncology royalties (PredictStreet / FinancialContent, 2025).

Takeda — mezagitamab Phase 3 dosing

PredictStreet also reports that Takeda dosed the first patient in a Phase 3 trial for mezagitamab in IgA Nephropathy, marking a late‑stage development catalyst for a Takeda‑linked royalty stream (PredictStreet / FinancialContent, 2025).

Castle Creek Biosciences

D‑Fi (FCX‑007), a gene therapy partnered with Castle Creek and targeting rare genetic disorders, is part of XOMA’s development‑stage royalty exposure, offering high upside tied to orphan indications (PredictStreet / FinancialContent, 2025).

Gossamer Bio

PredictStreet notes Seralutunib, an inhaled PDGFR/CSF1R/c‑KIT inhibitor partnered with Chiesi and Gossamer, where XOMA holds a low‑to‑mid single‑digit net royalty and anticipated Phase 3 PROSERA topline results (Phase 3 readout expected Feb 2026), representing a near‑term binary event (PredictStreet / FinancialContent, 2025).

AstraZeneca

Rilvegostomig (AZD2936), a TIGIT/PD‑1 bispecific partnered with AstraZeneca, is identified as a significant oncology pipeline asset contributing to XOMA’s royalty interests (PredictStreet / FinancialContent, 2025).

Rezolute

PredictStreet flags a clinical setback with Rezolute’s ersodetug, but positions XOMA’s strategy and late 2025 acquisitions (LAVA Therapeutics and Mural Oncology) as portfolio diversification moves that balance single‑asset volatility (PredictStreet / FinancialContent, 2025).

Talphera

DSUVIA® (sufentanil sublingual tablet), an acute pain treatment partnered with Talphera, is listed with a royalty range of 37.5% to 75% for DoD channels, an unusually high rate tied to specific government procurement terms (PredictStreet / FinancialContent, 2025).

Organon

XACIATO for bacterial vaginal infections, partnered with Organon, contributes a high single‑digit royalty rate to XOMA’s revenue mix, representing a marketed women’s health royalty (PredictStreet / FinancialContent, 2025).

Roche

VABYSMO® (faricimab‑svoa), an Ang‑2/VEGF‑A bispecific partnered with Roche, contributes a modest 0.5% royalty, a stable but small stream from a major ophthalmology product (PredictStreet / FinancialContent, 2025).

What the relationship map means for investors

  • Contracting posture: licensing and royalty‑first. XOMA’s revenues derive principally from licenses, royalties and sale of future revenue streams, which creates predictable, non‑operational cash receipts rather than product margin exposure (company filings).
  • Geographic breadth: U.S., EMEA and APAC exposure. The company reports primary income from the U.S., Europe and Asia‑Pacific, which diversifies regulatory and commercial risk across markets.
  • Concentration and criticality: diversified but asymmetrical. The portfolio mixes large pharma counterparties that deliver stability (Roche, Takeda, AstraZeneca, Novartis) and smaller biotechs that supply higher‑variance milestone upside.
  • Maturity profile: blended near‑term cash and pipeline optionality. Several marketed assets generate recurring royalties; other relationships are development‑stage and provide binary milestone events that can produce lumpy cash inflows.

If you want a tailored capital‑risk model built from this map and XOMA’s financials, start here: https://nullexposure.com/.

Key risks and monitoring priorities

  • Milestone concentration: material cash inflows are often tied to single events (approvals, PVR sales), creating headline risk and lumpiness.
  • Royalties skew low on many large‑partner assets: some royalties are fractional (e.g., 0.5% on Vabysmo), so portfolio scale matters.
  • Clinical/regulatory binary events: Phase 3 readouts (e.g., Gossamer/Seralutunib, Takeda/mezagitamab) are primary drivers of upside and downside.
  • Valuation sensitivity: XOMA’s market capitalization and EV multiples reflect expectations for continued milestone conversion and royalty realization; monitor announced sales or transfers of revenue streams for changes to cash flow timing.

Explore how these relationship signals update credit and valuation models at https://nullexposure.com/.

Bottom line

XOMA is a purpose‑built royalty aggregator: its value is a function of contract structure, clinical timelines and the quality of counterparties. For investors the right monitor set is straightforward—track partner regulatory events, milestone cash receipts, and any restructuring of royalty agreements — because those items materially alter both near‑term cash and long‑term valuation.